Last A$0.14 AUD
Change Today 0.00 / 0.00%
Volume 42.9K
NRT On Other Exchanges
Symbol
Exchange
NASDAQ CM
OTC US
Frankfurt
Stuttgart
As of 10:48 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

novogen ltd (NRT) Snapshot

Open
A$0.14
Previous Close
A$0.14
Day High
A$0.14
Day Low
A$0.14
52 Week High
12/17/14 - A$0.27
52 Week Low
11/19/14 - A$0.08
Market Cap
33.8M
Average Volume 10 Days
887.8K
EPS TTM
A$-0.04
Shares Outstanding
250.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVOGEN LTD (NRT)

Related News

No related news articles were found.

novogen ltd (NRT) Related Businessweek News

No Related Businessweek News Found

novogen ltd (NRT) Details

Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which include super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). Its SBPs technology platform offers drug candidates, which include Cantrixil, an intra-peritoneal product intended for the treatment of abdominal cancers, such as ovarian and pancreatic cancer; Trilexium that is intended for the treatment of neural cancers, including glioblastoma and neuroblastoma; and Trx-7 for the treatment of prostate cancer. The company’s ATMs technology platform targets the cytoskeleton of the cancer cell. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Founded in 1994

novogen ltd (NRT) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: A$332.8K
Company Secretary
Total Annual Compensation: A$57.5K
Vice-President of Drug Discovery, Manufacture...
Total Annual Compensation: A$279.0K
Director of ATM Program
Total Annual Compensation: A$52.5K
Chief Scientific Officer
Total Annual Compensation: A$200.0K
Compensation as of Fiscal Year 2014.

novogen ltd (NRT) Key Developments

Novogen Limited Announces Consolidated Earnings Results for the Half-Year Ended December 31, 2014

Novogen Limited announced consolidated earnings results for the half-year ended December 31, 2014. For the period, revenue was $5,565 against $29,206 a year ago. Loss before income tax expense was $2,434,394 against $3,069,898 a year ago. Loss for the half-year is attributable to owners of the company was $2,247,407 against $3,055,263 a year ago. Basic and diluted earnings per share were 1.274 cents against 2.108 cents a year ago. Net cash used in operating activities was $1,475,630 against $2,100,814 a year ago. Payments for property, plant and equipment was $4,272 against $11,357 a year ago.

Novogen Limited Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 02:30 PM

Novogen Limited Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 02:30 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Graham Edmund Kelly, Executive Chairman and Chief Executive Officer.

Novogen Limited Lodges Key Super-Benzopyran Patent

Novogen Limited announced the lodgement of final specifications of a patent that covers the company's first family of super-benzopyran compounds that to date has yielded drug candidates TRXE-002, TRXE-009 and TRXE-0025. Super-benzopyrans represent a new chemical structure of increasing complexity and diversity. Based on the degree of that complexity, Novogen chemists have identified at least 6 patent families of related compounds. The final patent specifications just lodged represent the first of those families, with some hundreds of molecules designed and manufactured over the past 12 months. The focus with this particular family of compounds has been their ability to kill cancer stem cells. The underlying pharmacophore responsible for this activity has been identified and forms a key aspect of the patent. Work is progressing on the remaining 5 potential patent families to determine the underlying pharmacophores relevant to various activities including the promotion of neurogenesis, to the promotion of functionality of stem cells with genetic abnormalities, and to the treatment of lysosomal storage diseases. Once those potential patent families have been reduced to practice, then the appropriate patents will be lodged.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRT:AU A$0.14 AUD 0.00

NRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRT.
View Industry Companies
 

Industry Analysis

NRT

Industry Average

Valuation NRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.4x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOGEN LTD, please visit www.novogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.